¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¼¼ºê¶õ½º °£ ½ÉÆ÷Áö¾ö : 2022-02-12±³À°ÀÏÀÚ : 2022-02-12
±³À°Àå¼Ò : ½ºÀ§½º±×·£µåÈ£ÅÚ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) ¼¼ºê¶õ½º °£ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ¼¼ºê¶õ½ºº´¿ø
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 02-2228-5223
À̸ÞÀÏ :
lccrc1208@yuhs.ac ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 09:00~09:25 Current status and future perspectives of NA therapy in CHB ÀÓÇüÁØ(°í·Á´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 09:25~09:50 HCC risk after HBsAg loss ½Åµ¿Çö(¼º±Õ°ü´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 09:50~10:15 Clinical research on chronic viral hepatitis utilising electronic medical records in Hong Kong Terry Cheuk-Fung Yip(Faculty of Medicine The Chinese University of Hong Kong Hong Kong)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 10:15~10:40 Establishment of a nationwide prospective Korean CHB cohort ÀÌÀç½Â(¿¬¼¼´ë)
Åä·Ð 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 10:40~10:50 Discussion ()
ÈÞ½Ä 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 10:50~11:00 Session break ()
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 11:00~11:25 Fat does matter? Àü´ë¿ø(ÇѾç´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 11:25~11:50 Follow-up or not to follow-up NAFLD patients ÀÌÇý¿ø(¿¬¼¼´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 11:50~12:15 Association between NAFLD and CKD Á¤Âù¿µ(¿¬¼¼´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 12:15~12:40 Influence of exercise on NAFLD ÀüÈ£¼ö(ÀÌÈ¿©´ë)
Åä·Ð 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 12:40~12:50 Discussion ()
½Ä»ç 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 12:50~13:30 Lunch ()
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 13:30~13:55 Implication of YAP/TAZ signaling and novel therapeutic targets ³ë¿ø»ó(°æÈñ´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 13:55~14:20 Breakthrough in HCC surveillance: perspective of MR surveillance ÀÌÇüÁø(¿¬¼¼´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 14:20~14:45 Immunological classification of HCC ±èÇý·É(¼¿ï´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 14:45~15:10 Application of artificial intelligence in HCC diagnosis ±è¼º¿ø(¿¬¼¼´ë)
Åä·Ð 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 15:10~15:20 Discussion ()
ÈÞ½Ä 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 15:20~15:30 Session break ()
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 15:30~15:55 How far can criteria be expanded in living donor liver transplantation? ÁÖµ¿Áø(¿¬¼¼´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 15:55~16:20 Yttrium-90 transarterial radioembolization: 13-year experiences in Severance Hospital ±è°æ¹Î(¿¬¼¼´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 16:20~16:45 Novel radiation therapy: Carbon ion for HCC ¼ºÁø½Ç(¿¬¼¼´ë)
±³À°½Ã°£ 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 16:45~17:10 Systemic therapy for HCC: TKI vs. checkpoint inhibitor TBD()
Åä·Ð 02-12 ½ºÀ§½º±×·£µåÈ£ÅÚWhite Heron 17:10~17:20 Discussion ()